Literature DB >> 2424860

The effect of ergobromocriptine on serum testosterone and prolactin levels in patients with carcinoma of the prostate.

C Taşar, A Akdaş, Z Kirkali.   

Abstract

The effect of Ergobromocriptine treatment on serum testosterone and prolactin levels in 15 patients with prostatic carcinoma and 15 patients with benign prostatic hyperplasia was examined. The prolactin levels which were elevated in patients with prostatic carcinoma showed a significant decrease after suppression with Ergobromocriptine. The selective effect of Ergobromocriptine on prolactin levels of patients with prostatic carcinoma may control the progression of the disease.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2424860     DOI： 10.1007/bf02082651

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  12 in total

1.  Regulation of prolactin binding sites in the seminal vesicle, prostate gland, testis and liver of intact and castrated adult rats: effect of administration of testosterone, 2-bromo-alpha-ergocryptine and fluphenazine.

Authors:  R J Barkey; J Shani; D Barzilai
Journal:  J Endocrinol       Date:  1979-04       Impact factor: 4.286

2.  Endocrine profile of a specific prolactin inhibitor: Br-ergocryptine (CB 154). A preliminary report.

Authors:  E Del Pozo; H Friesen; P Burmeister
Journal:  Schweiz Med Wochenschr       Date:  1973-06-09

3.  Effect of prolactin on testosterone uptake by the perfused canine prostate.

Authors:  M I Resnick; D J Walvoord; J T Grayhack
Journal:  Surg Forum       Date:  1974

4.  Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion.

Authors:  R M MacLeod; J E Lehmeyer
Journal:  Endocrinology       Date:  1974-04       Impact factor: 4.736

5.  Prolactin, LH, TSH, T3 and T4 in patients with urogenital carcinomas.

Authors:  U Dunzendorfer; M Knöner; D Drahowsky
Journal:  Urol Int       Date:  1979       Impact factor: 2.089

6.  Measurements of prolactin and androgens in patients with prostatic diseases.

Authors:  J Saroff; R Y Kirdani; T M Chu; Z Wajsman; G P Murphy
Journal:  Oncology       Date:  1980       Impact factor: 2.935

7.  Plasma steroid and protein hormone concentrations in patients with benign prostatic hypertrophy and in normal men.

Authors:  E Ortega; E Ruiz; M C Mendoza; A Martin-Andres; C Osorio
Journal:  Experientia       Date:  1979-06-15

8.  [Bromocriptine for palliation of advanced prostatic carcinoma. Experimental and clinical profile of a drug (author's' transl)].

Authors:  G H Jacobi; J E Altwein
Journal:  Urol Int       Date:  1979       Impact factor: 2.089

9.  Localization of prolactin binding in prostate and testis: The role of serum prolactin concentration on the testicular LH receptor.

Authors:  C Aragona; H G Bohnet; H G Friesen
Journal:  Acta Endocrinol (Copenh)       Date:  1977-02

10.  Bromocriptine and prostatic carcinoma: plasma kinetics, production and tissue uptake of 3H-testosterone in vivo.

Authors:  G H Jacobi; K Sinterhauf; K H Kurth; J E Altwein
Journal:  J Urol       Date:  1978-02       Impact factor: 7.450
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.